mk 287 has been researched along with bepafant in 1 studies
Studies (mk 287) | Trials (mk 287) | Recent Studies (post-2010) (mk 287) | Studies (bepafant) | Trials (bepafant) | Recent Studies (post-2010) (bepafant) |
---|---|---|---|---|---|
6 | 0 | 0 | 174 | 0 | 5 |
Protein | Taxonomy | mk 287 (IC50) | bepafant (IC50) |
---|---|---|---|
Platelet-activating factor receptor | Cavia porcellus (domestic guinea pig) | 0.073 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bures, MG; Carrera, GM; Davidsen, SK; Guinn, DE; Heyman, HR; May, PD; Phillips, JG; Pireh, D; Sheppard, GS; Steinman, DH | 1 |
1 other study(ies) available for mk 287 and bepafant
Article | Year |
---|---|
3-(2-(3-Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists.
Topics: Administration, Oral; Animals; Capillary Permeability; Edema; In Vitro Techniques; Indoles; Magnetic Resonance Spectroscopy; Male; Mice; Platelet Activating Factor; Rabbits; Rats; Rats, Sprague-Dawley; Serotonin; Skin; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 1994 |